INS and type 2 diabetes mellitus: When it comes to the use of antidiabetic medications in our T2DM-CKDs, 40% of patients are taking metformin, 38.3% sulfonylureas, 32.7% DPP-4 inhibitors, 26.6% insulin 7.9% GLP-1 analogues, 6.7% repaglinide, 5.9% SGLT-2 inhibitors, 5.3% pioglitazone, 0.7% acarbose.